Global Neoantigen Cancer Vaccine Market By Product (Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine), By Neoantigen Type (Nucleic Acid, Dendritic Cell, Tumor Cell, Synthetic long peptide (SLP)), By Route of Administration (Intravenous,

Global Neoantigen Cancer Vaccine Market By Product (Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine), By Neoantigen Type (Nucleic Acid, Dendritic Cell, Tumor Cell, Synthetic long peptide (SLP)), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (Whole Genome Sequencing, Others), By Delivery Mechanism (Gene gun, Electroporation, Others), By Application (Melanoma, Brain Cancer, Others), By Region, Competition, Forecast & Opportunities, 2025

Global neoantigen cancer vaccine market is projected to grow at a CAGR of close to 35% during the forecast period. The key factor responsible for the growth of neoantigen cancer vaccine market is rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to bode well for the growth of neoantigen cancer vaccine market across the globe in the coming years. Moreover, rising cases of cancers is further anticipated to bolster the market growth through 2025.

The global neoantigen cancer vaccine market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment dominated the market until 2019 and is further anticipated to be the fastest-growing application segment of the neoantigen cancer vaccine market during the forecast period as well. This growth can be accredited to quick response as well as the to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment over the coming years.

Major players operating in the global neoantigen cancer vaccine market include Avidea Technologies, Agenus, Roche, Nouscom, Merck, Pfizer, Advaxis, Medigene, Genocea Biosciences, Gritstone Oncology, Gilead Sciences, Eli Lilly, Novogene, Moderna, BioNTech, Ziopharm, ISA Pharmaceutical, Vaccibody, Brightpath Bio, Vaximm, etc. The companies operating in the market across the globe are focussing more towards expanding their share in the market.

Years considered for this report:

Historical Years: 2015-2018
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2021–2025

Objective of the Study:

To analyse and forecast the market size of global neoantigen cancer vaccine market.
To classify and forecast global neoantigen cancer vaccine market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution.
To identify drivers and challenges for global neoantigen cancer vaccine market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neoantigen cancer vaccine market.
To conduct pricing analysis for global neoantigen cancer vaccine market.
To identify and analyse the profile of leading players operating in global neoantigen cancer vaccine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the new products, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global neoantigen cancer vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

Neoantigen cancer vaccine manufacturers, suppliers, distributors and other stakeholders
Government bodies such as regulating authorities and policy makers
Organizations, forums and alliances related to neoantigen cancer vaccine
Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global neoantigen cancer vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Product:


Personalized neo-antigen vaccine
Off-the shell neoantigen vaccine
Market, By Neoantigen Type:
Nucleic acid
Dendritic cell
Tumor cell
Synthetic Long Peptide
Market, By Route of Administration:
Intravenous
Intramuscular
Transdermal
Others
Market, By Cell:
Autologous
Allogenic
Market, By Technology:
Whole Genome Sequencing
RNA Sequencing
HLA Typing
Market, By Delivery Mechanism:
Gene gun
Electroporation
Liposomes
Virosomes
Others

Market, By Application:


Melanoma
Brain cancer
Gastrointestinal
Lung
Others

Market, By Region:


North America
United States
Mexico
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Middle East and Africa
South Africa
Saudi Arabia
UAE
South America
Brazil
Argentina
Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global neoantigen cancer vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Product Overview
2. Research Methodology
3. Executive Summary
4. Global Neoantigen Cancer Vaccine Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value & Volume
4.2. Market Share & Forecast
4.2.1. By Product (Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine)
4.2.2. By Neoantigen Type (Nucleic acid, Dendritic cell, Tumor cell and Synthetic long peptide (SLP))
4.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
4.2.4. By Cell (Autologous, Allogenic)
4.2.5. By Technology (Whole Genome Sequencing, RNA Sequencing, HLA Typing)
4.2.6. By Delivery Mechanism (Gene gun, Electroporation, Liposomes, Virosomes and Others)
4.2.7. By Application (Melanoma, Brain cancer, Gastrointestinal, Lung and Others)
4.2.8. By Company (2019)
4.2.9. By Region
4.3. Market Attractiveness Index
5. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Product
5.2.2. By Neoantigen Type
5.2.3. By Route of Administration
5.2.4. By Cell
5.2.5. By Technology
5.2.6. By Application
5.2.7. By Country
5.3. Market Attractiveness Index
5.4. Asia-Pacific: Country Analysis
5.4.1. China Neoantigen Cancer Vaccine Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Product
5.4.1.2.2. By Neoantigen Type
5.4.1.2.3. By Route of Administration
5.4.1.2.4. By Cell
5.4.1.2.5. By Technology
5.4.1.2.6. By Application
5.4.2. India Neoantigen Cancer Vaccine Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Product
5.4.2.2.2. By Neoantigen Type
5.4.2.2.3. By Route of Administration
5.4.2.2.4. By Cell
5.4.2.2.5. By Technology
5.4.2.2.6. By Application
5.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Product
5.4.3.2.2. By Neoantigen Type
5.4.3.2.3. By Route of Administration
5.4.3.2.4. By Cell
5.4.3.2.5. By Technology
5.4.3.2.6. By Application
5.4.4. South Korea Neoantigen Cancer Vaccine Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Product
5.4.4.2.2. By Neoantigen Type
5.4.4.2.3. By Route of Administration
5.4.4.2.4. By Cell
5.4.4.2.5. By Technology
5.4.4.2.6. By Application
5.4.5. Singapore Neoantigen Cancer Vaccine Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Product
5.4.5.2.2. By Neoantigen Type
5.4.5.2.3. By Route of Administration
5.4.5.2.4. By Cell
5.4.5.2.5. By Technology
5.4.5.2.6. By Application
5.4.6. Australia Neoantigen Cancer Vaccine Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Product
5.4.6.2.2. By Neoantigen Type
5.4.6.2.3. By Route of Administration
5.4.6.2.4. By Cell
5.4.6.2.5. By Technology
5.4.6.2.6. By Application
6. Europe Neoantigen Cancer Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Neoantigen Type
6.2.3. By Route of Administration
6.2.4. By Cell
6.2.5. By Technology
6.2.6. By Application
6.2.7. By Country
6.3. Market Attractiveness Index
6.4. Europe: Country Analysis
6.4.1. France Neoantigen Cancer Vaccine Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Product
6.4.1.2.2. By Neoantigen Type
6.4.1.2.3. By Route of Administration
6.4.1.2.4. By Cell
6.4.1.2.5. By Technology
6.4.1.2.6. By Application
6.4.2. Germany Neoantigen Cancer Vaccine Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Product
6.4.2.2.2. By Neoantigen Type
6.4.2.2.3. By Route of Administration
6.4.2.2.4. By Cell
6.4.2.2.5. By Technology
6.4.2.2.6. By Application
6.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Product
6.4.3.2.2. By Neoantigen Type
6.4.3.2.3. By Route of Administration
6.4.3.2.4. By Cell
6.4.3.2.5. By Technology
6.4.3.2.6. By Application
6.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
6.4.4.1. Market Size & Forecast
6.4.4.1.1. By Value
6.4.4.2. Market Share & Forecast
6.4.4.2.1. By Product
6.4.4.2.2. By Neoantigen Type
6.4.4.2.3. By Route of Administration
6.4.4.2.4. By Cell
6.4.4.2.5. By Technology
6.4.4.2.6. By Application
6.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
6.4.5.1. Market Size & Forecast
6.4.5.1.1. By Value
6.4.5.2. Market Share & Forecast
6.4.5.2.1. By Product
6.4.5.2.2. By Neoantigen Type
6.4.5.2.3. By Route of Administration
6.4.5.2.4. By Cell
6.4.5.2.5. By Technology
6.4.5.2.6. By Application
7. North America Neoantigen Cancer Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Neoantigen Type
7.2.3. By Route of Administration
7.2.4. By Cell
7.2.5. By Technology
7.2.6. By Application
7.2.7. By Country
7.3. Market Attractiveness Index
7.4. North America: Country Analysis
7.4.1. United States Neoantigen Cancer Vaccine Market Outlook
7.4.1.1. Market Size & Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share & Forecast
7.4.1.2.1. By Product
7.4.1.2.2. By Neoantigen Type
7.4.1.2.3. By Route of Administration
7.4.1.2.4. By Cell
7.4.1.2.5. By Technology
7.4.1.2.6. By Application
7.4.2. Mexico Neoantigen Cancer Vaccine Market Outlook
7.4.2.1. Market Size & Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share & Forecast
7.4.2.2.1. By Product
7.4.2.2.2. By Neoantigen Type
7.4.2.2.3. By Route of Administration
7.4.2.2.4. By Cell
7.4.2.2.5. By Technology
7.4.2.2.6. By Application
7.4.3. Canada Neoantigen Cancer Vaccine Market Outlook
7.4.3.1. Market Size & Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share & Forecast
7.4.3.2.1. By Product
7.4.3.2.2. By Neoantigen Type
7.4.3.2.3. By Route of Administration
7.4.3.2.4. By Cell
7.4.3.2.5. By Technology
7.4.3.2.6. By Application
8. South America Neoantigen Cancer Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Neoantigen Type
8.2.3. By Route of Administration
8.2.4. By Cell
8.2.5. By Technology
8.2.6. By Application
8.2.7. By Country
8.3. Market Attractiveness Index
8.4. South America: Country Analysis
8.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Product
8.4.1.2.2. By Neoantigen Type
8.4.1.2.3. By Route of Administration
8.4.1.2.4. By Cell
8.4.1.2.5. By Technology
8.4.1.2.6. By Application
8.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Product
8.4.2.2.2. By Neoantigen Type
8.4.2.2.3. By Route of Administration
8.4.2.2.4. By Cell
8.4.2.2.5. By Technology
8.4.2.2.6. By Application
8.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Product
8.4.3.2.2. By Neoantigen Type
8.4.3.2.3. By Route of Administration
8.4.3.2.4. By Cell
8.4.3.2.5. By Technology
8.4.3.2.6. By Application
9. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Neoantigen Type
9.2.3. By Route of Administration
9.2.4. By Cell
9.2.5. By Technology
9.2.6. By Application
9.2.7. By Country
9.3. Market Attractiveness Index
9.4. MEA: Country Analysis
9.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Product
9.4.1.2.2. By Neoantigen Type
9.4.1.2.3. By Route of Administration
9.4.1.2.4. By Cell
9.4.1.2.5. By Technology
9.4.1.2.6. By Application
9.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Product
9.4.2.2.2. By Neoantigen Type
9.4.2.2.3. By Route of Administration
9.4.2.2.4. By Cell
9.4.2.2.5. By Technology
9.4.2.2.6. By Application
9.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Product
9.4.3.2.2. By Neoantigen Type
9.4.3.2.3. By Route of Administration
9.4.3.2.4. By Cell
9.4.3.2.5. By Technology
9.4.3.2.6. By Application
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
12. Competitive Landscape
12.1. Competition Outlook
12.2. Players Profiled (Leading Companies)
12.2.1. Avidea Technologies
12.2.2. Agenus
12.2.3. Roche
12.2.4. Nouscom
12.2.5. Merck
12.2.6. Pfizer
12.2.7. Advaxis
12.2.8. Medigene
12.2.9. Genocea Biosciences
12.2.10. Gritstone Oncology
12.2.11. Gilead Sciences
12.2.12. Eli Lilly
12.2.13. Novogene
12.2.14. Moderna
12.2.15. BioNTech
12.2.16. Ziopharm
12.2.17. ISA Pharmaceutical
12.2.18. Vaccibody
12.2.19. Brightpath Bio
12.2.20. Vaximm
13. Strategic Recommendations
14. About Us & Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook